Dr Liliane Fossati-Jimack
Senior Manager / Senior Scientific Officer
Centre: Experimental Medicine and Rheumatology
Email: firstname.lastname@example.orgTelephone: +44(0)20 7882 8194
ORCID iD: https://orcid.org/0000-0003-3757-3999
I’ve obtained both my degree (Biology) and PhD at the University of Geneva in Switzerland. My interest turned rapidly towards the dysregulation of the immune system in the autoimmune disease Systemic Lupus Erythematosus. I moved to London to further my career at Imperial College London.
Moving to the Centre for Experimental Medicine and Rheumatology (EMR) at Queen Mary University of London, my interest moved to another autoimmune disease - Rheumatoid Arthritis. My role within EMR has evolved and I became heavily involved in the co-management and delivery of the R4RA and STRAP clinical trials, contributing to the landmark publication of the R4RA trial in The Lancet last year. I have now taken on the role of Senior Project Manager within EMR providing both scientific and managerial direction for key studies within the centre.
- Fossati, L. et al. The Yaa gene‐mediated acceleration of murine lupus: Yaa−T cells from non‐autoimmune mice collaborate with Yaa+B cells to produce lupus autoantibodies in vivo. Eur. J. Immunol. 25, 3412–3417 (1995).
- Fossati-Jimack, L. et al. Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fcγ receptor III. J. Exp. Med. 191, 1293–1302 (2000).
- Fossati-Jimack, L. et al. Phagocytosis Is the Main CR3-Mediated Function Affected by the Lupus-Associated Variant of CD11b in Human Myeloid Cells. PLoS One 8, (2013).
- Fossati-Jimack, L. et al. Intranasal peptide-induced tolerance and linked suppression: Consequences of complement deficiency. Immunology 144, 149–157 (2015).
- Humby, F. et al. Rituximab versus Tocilizumab in anti-TNF inadequate responder patients with Rheumatoid Arthritis (R4RA): a stratified, biopsy-driven, multi-centre, randomised, open label, controlled clinical trial – 16 week outcomes. Lancet 397, 305–317 (2021).